Abstract
CL 259,763, N-[4-[(4-fluorophenyl)sulfonyl]phenyl] acetamide, is an orally active compound capable of modifying the reactivity of certain lymphoid cell populations affected by the growth of a tumor. The compound augmented the response of lymphocytes from tumor-primed animals to syngeneic tumor cells, resulting in a marked increase in tumor cell destruction. Likewise, it enhanced macrophage inhibitory effects on the growth of tumor cells in vitro. These “activated” macrophages were detectable in peritoneal exudates of treated mice 4 to 12 days after receiving a single oral dose of CL 259,763, with peak activity being demonstrable by day 7. The compound also restored the alloreactivity of lymphocytes from immunodepressed mice bearing the Lieberman plasma cell tumor, possibly by interferring with suppressor cells. Macrophages and lymphocytes from treated mice released significantly more IL-1 and IL-2-like factors in culture than did the control counterparts. Sera from treated mice also possessed more colony stimulating factor than those from normal mice. Immunoadjuvant effects were evident when the compound was administered with an inactivated L1210 leukemia vaccine and it enhanced the effectiveness of cytotoxic chemotherapy when given to mice challenged with P388 murine leukemia. These immunomodulating effects of CL 259,763 may hopefully be exploited in efforts to augment the immune response of the host to a progressively growing tumor.
Keywords: Leukemia, Single Oral Dose, Acetamide, Treated Mouse, Sulfonyl
References
- 1.Bast RC, Berek JS, Obrist R, Griffiths CT, Berkowitz RS, Hacker NF, Parker L, Lagasse LD, Knapp RC. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum . Cancer Res. 1983;43:1395–1401. [PubMed] [Google Scholar]
- 2.Burnet FM. Immunological surveillance in neoplasia. Transplant Rev. 1971;7:3–25. doi: 10.1111/j.1600-065x.1971.tb00461.x. [DOI] [PubMed] [Google Scholar]
- 3.Chen Y, Hwang LT, Heller P. Immunosuppression in plasmacytoma: induction of suppressor cells. Clin Exp Immunol. 1982;47:191–196. [PMC free article] [PubMed] [Google Scholar]
- 4.Chow DA, Green MI, Greenberg AH. Macrophage-dependent, NK-cell-independent “natural” surveillance of tumors in syngeneic mice. Int J Cancer. 1979;23:788–791. doi: 10.1002/ijc.2910230609. [DOI] [PubMed] [Google Scholar]
- 5.Dillman RO, Beauregard JC, Mendelsohn J, Green MR, Howell SB, Royston I. Phase I trials of thymosin fraction 5 and thymosin α-1. J Biol Response Mod. 1982;1:35–41. [Google Scholar]
- 6.Eilber FR, Morton DL. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer. 1970;25:362–367. doi: 10.1002/1097-0142(197002)25:2<362::aid-cncr2820250213>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
- 7.Evans CH. Lymphokines, homeostasis, and carcinogenesis. J Natl Cancer Inst. 1983;71:253–257. [PubMed] [Google Scholar]
- 8.Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. In: Lynch HT, editor. Cancer genetics. Springfield, IL.: Charles Thomas; 1976. pp. 63–75. [Google Scholar]
- 9.Katzmann JA. Myeloma-induced immunosuppression: a multistep mechanism. J Immunol. 1978;121:1405–1409. [PubMed] [Google Scholar]
- 10.Kennard J, Zolla-Pazner S. Origin and function of suppressor macrophages in myeloma. J Immunol. 1980;124:268–273. [PubMed] [Google Scholar]
- 11.Lamm KL, Thor DE, Harris SC, Stogdill VD, Radwin HM. Intravesical and percutaneous BCG immunotherapy of recurrent superficial bladder cancer. In: Terry WD, Rosenberg SA, editors. Immunotherapy of human cancer. New York: Excerpte Medica; 1982. pp. 315–322. [Google Scholar]
- 12.Law LW. Neoplasms in thymectomized mice following room infection with polyoma virus. Nature. 1965;205:672–673. doi: 10.1038/205672a0. [DOI] [PubMed] [Google Scholar]
- 13.Lichtenstein A, Murahata R, Sugasawara R, Zighelboim J. Suppressor T cells and suppressor macrophages induced by Corynebacterium parvum . Cell Immunol. 1981;58:257–268. doi: 10.1016/0008-8749(81)90219-7. [DOI] [PubMed] [Google Scholar]
- 14.Lotze MT, Robb RJ, Sharrow SO, Frana LW, Rosenberg SA. Systemic administration of interleukin-2 in humans. J Biol Response Mod. 1984;3:475–482. [PubMed] [Google Scholar]
- 15.Louie A, Gallagher J, Sikora K, Levy R, Rosenberg S, Merigan T. Follow-up observations on the effect of human leukocyte interferon on non-Hodgkin's lymphoma. Blood. 1981;58:712–718. [PubMed] [Google Scholar]
- 16.Mackaness GB. Role of macrophages in host defense mechanism. In: Fink MA, editor. The macrophage in neoplasia. New York: Academic Press Inc; 1976. pp. 3–13. [Google Scholar]
- 17.Oldham RK. Biological response modifiers. J Natl Cancer Inst. 1983;70:789–796. [PubMed] [Google Scholar]
- 18.Ritz J, Schlossman SF. Utilization of monoclonal antibodies in treatment of leukemia and lymphoma. Blood. 1982;59:1–11. [PubMed] [Google Scholar]
- 19.Schwartz RS. Another look at immunologic surveillance. New Engl J Med. 1975;293:181–184. doi: 10.1056/NEJM197507242930406. [DOI] [PubMed] [Google Scholar]
- 20.Warner JF, Dennert G. Effects of a cloned cell line with NK activity on bone marrow transplants, tumor development and metastasis in vivo. Nature. 1982;300:31–34. doi: 10.1038/300031a0. [DOI] [PubMed] [Google Scholar]
- 21.Yu AS, Bernstein ID. T helper cells in immune mice amplify the primary anti-tumor cytotoxic response. J Immunol. 1982;129:856–859. [PubMed] [Google Scholar]
- 22.Zolla S. Effect of plasmacytomas on the immune response of mice. J Immunol. 1972;108:1039–1048. [PubMed] [Google Scholar]